Status:
COMPLETED
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
Lead Sponsor:
Pfizer
Conditions:
Lung Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effective in the tre...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed stage IIIB (inicluding those with pleural effusion), IV or recurrent non-small cell lung cancer (nsclc).
- Bidimensionally measurable disease \>2cm x 1 cm by conventional CT Scan or \>1 cm x 1cm by spiral CT Scan.
Exclusion
- No tumors in close proximity to major veins or arteries.
- No sanguinous pleural effusion due to disease or pericardial effusion suspicious for disease.
- No evidence or history brain metastases.
Key Trial Info
Start Date :
May 1 2002
Trial Type :
INTERVENTIONAL
End Date :
March 1 2005
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT00074854
Start Date
May 1 2002
End Date
March 1 2005
Last Update
November 9 2006
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Greenbrae, California, United States, 94904
2
Pfizer Investigational Site
San Mateo, California, United States, 94402
3
Pfizer Investigational Site
San Pablo, California, United States, 94806
4
Pfizer Investigational Site
Tampa, Florida, United States, 33612-9497